Navigation Links
Raindrop® Medication Nebulizer - Adult Aerosol Mask & Tubing

ProductsRaindrop® Medication Nebulizer - Adult Aerosol Mask & Tubing
Company Nellcor
Item Raindrop® Medication Nebulizer - Adult Aerosol Mask & Tubing
Features 
  • Medication Nebulizer
  • Adult aerosol mask
  • 7ft tubing
  • 50/case
Description The Raindrop® medication nebulizer achieves optimum lung penetration for maximum therapeutic benefit. Documented MMAD particle size range is 1.04-1.10 µ at 6-8 LPM. Latex-free components. Usable with compressor or air outlet.

As the world leader in airway management products, Nellcor gives healthcare providers the assurance of proven technology by offering top brands in the industry. Our unmatched selection of products includes Mallinckrodt® Endotracheal Tubes and specialty airways, Shiley® Tracheostomy Tubes, DAR® Filters, Easy Cap® CO2 Detectors, and resuscitation bags. Through our association with Puritan Bennett, a leader in critical care ventilators, you have access to complete systems for critical care. Click on the links below for more product information.
Info Nellcor
Customer Service: (800) 635-5267
Web site: http://www.nellcor.com/

Related medicine products :

1. Raindrop® Medication Nebulizer - Mouthpiece, Tee Adapter, Reservoir & Tubing
2. Raindrop® Medication Nebulizer - Universal Tip, Tubing, Mouthpiece, Tee Adapter & Reservoir
3. Raindrop® Medication Nebulizer - Tee Adapter, Mouthpiece & Reservoir
4. Raindrop® Medication Nebulizer - Tee Adapter & Mouthpiece
5. Raindrop® Medication Nebulizer - Pediatric Aerosol Mask & Tubing
6. Raindrop® Medication Nebulizer
7. Flo-Mist™ Continuous Medication Nebulizer (CMN) - Adult Kits
8. 007761 Medication Nebulizer Kit
9. 007762 Medication Nebulizer Kit
10. 007763 Medication Nebulizer Kit
11. 007764 Medication Nebulizer Kit
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures.
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor.
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains.
Medicine Products:
(Date:5/16/2008)... AIDS Vaccine is Possible and,Still Urgently Neede...Twenty-five years since the,discovery of HIV, the ...,the AIDS pandemic. Scientists have learned a trem...er pathogen, and have developed more drugs to,trea... this progress is not,enough. While it is vital to...
(Date:5/16/2008)...ewswire/ -- Less than a week after,committing medi...tated by,Cyclone Nargis, Project HOPE, an internat... organization, is again mobilizing its full,resour...r the people of,central China devastated by the ma...ves., "I am saddened by the vast loss of life and...
(Date:5/16/2008)... abstracts or poster presentations at the annual m...y (ASCO) to be held in Chicago, Illinois, May 30 ...arly Detection of Malignant Pleural Mesothelioma ...ly detection and prognostic marker,in malignant p... Pass, M.D., professor of cardiothoracic surgery a...
(Date:5/16/2008)...wire/ -- Behavioral healthcare,systems are playing...llions,of Americans of all ages who experience psy...ccording to the latest annual survey from the,Nati...PHS) released today., The 2007 NAPHS Annual Surve...care delivery. One chapter provides a trend analys...
Breaking Medicine News(10 mins):Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 2Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 3Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 4Health News:New NAPHS Annual Survey Tracks Behavioral Treatment Trends 2
...the scientists at the Glasgow University, English ...xidants that offer protection against stroke, hear...as effective as an apple in keeping the doctor awa...effects by getting 12 volunteers to drink a pint a...
...rehensive scan of the human genome to date linked ...veloping alcoholism has been completed by research...National Institute on Drug Abuse (NIDA), National ...e that the new genomic technology has been used to...
...ucted among many Canadian households has revealed ...able to realize timely medical guidance and facili... The Decima poll conducted amongst 3,000 Canadi...eholds required medical care during the previous t...
...ve devised a method to outwit cancer cells and ins... of cancer cells. This novel discovery could unloc...ery works on the known principle that involves the...es, to check the abnormal growth of cells; the way...
Other Medicine News:Health News:Study to Identify People at Risk of Alcoholism 2Health News:Study to Identify People at Risk of Alcoholism 3
(Date:5/16/2008)...sults demonstrating that TYKERB and trastuzumab to...on of progression-free survival (PFS), -- Combini...e and,outside of the HER2 receptor may create a mo...activity of TYKERB alone despite patients,previou... chemotherapy, LONDON and PHILADELPHIA, May 16 /P...
(Date:5/16/2008)...tically Significant Reductions in Selected ...to be published in 2008 Proceedings of the America...cology, SAN DIEGO, May 16 /PRNewswire-FirstCall/ ...nounced today that, in a registrational bioequival...tically significant reduction,in general disorders...
(Date:5/15/2008)...ta highlight safety profile of BSI-201 in ...ISBANE, Calif., May 15 /- BiPar Scien...any developing novel cancer therapies,today annou... BSI-201, will,be presented at the 2008 American S...ago., Findings will be presented from the first i...
(Date:5/15/2008)...RNewswire-FirstCall/ -- Schering-Plough,Corporatio... and treatment of,chronic hepatitis C virus (HCV) ...clinical studies with PEGINTRON(TM) (peginterferon...ion therapy, as well as boceprevir, the,company,s ...be presented at,the 39th annual Digestive Disease ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 1Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 2Study finds widespread vitamin and mineral use among cancer survivors 10729 1Study finds widespread vitamin and mineral use among cancer survivors 10729 2Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 1Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 2Unintended Errors Leave Many Newborns Vulnerable 10721 1Unintended Errors Leave Many Newborns Vulnerable 10721 2
...Genex Technologies,Inc. announced today data from ...n with docetaxel in patients with metastatic breas... Cancer Institute,of Canada - Clinical Trials Grou...2007 Annual Meeting in Los Angeles, Calif. , , ...ients treated, five patients (33.3 percent) showed...
...esearchers from the,Barbara Ann Karmanos Cancer In...oday that an antibiotic typically prescribed for,A...ly treating,certain types of cancers. , Q. Ping Do...and,members of his lab announced the findings of t...ppears to have an anti-tumor effect,in mice bearin...
Other Medicine Technology:OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 2OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 3OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 4Alzheimer's Drug Shows Promise in Fighting Cancer 2